Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-21-1429
Abstract: HER3 is ubiquitously expressed in EGFR-mutant non-small cell lung cancer (NSCLC) irrespective of resistant mechanisms to EGFR tyrosine kinase inhibitors, thus garnering attention as a valuable therapeutic target. In this issue of Cancer Discovery, Jänne… read more here.
Keywords: patritumab deruxtecan; egfr tki; deruxtecan paving; tki resistant ... See more keywords